TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24254339

Group type: EXPERIMENTAL
Intervention: Dilation-assisted stone extraction (group A)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Endoscopic sphincterotomy (EST) (group B)
Number of subjects: 462
Study: 22414688

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) 0, 100, 250, and 500 g
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Red beetroot-enriched bread (100 g)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Total urinary nitrate/nitrite (NO(x)) after BJ consumption
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Total urinary nitrate/nitrite (NO(x)) after red beetroot-enriched bread ingestion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control bread (0 g beetroot)
Number of subjects: 32
Study: 21079163

Group type: EXPERIMENTAL
Intervention: Buffered preservative‐free acidified solution in saline nasal spray
Number of subjects: 20

Group type: COMPARATOR
Intervention: Benzalkonium chloride‐containing saline nasal spray
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both nasal spray solutions
Number of subjects: 20
Study: 18946193

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15924527

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 12847284

Group type: EXPERIMENTAL
Intervention: Live recombinant canarypox ALVAC-HIV vaccine with or without rgp120/SF-2
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10439770

Group type: COMPARATOR
Intervention: Granisetron 2.5 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 120
Study: 8537681

Group type: EXPERIMENTAL
Intervention: Two doses of 10(7) TCID50 of live, attenuated cold‐adapted influenza A/Kawasaki/86 (H1N1) reassortant virus vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two doses of 10(7) TCID50 of ca influenza virus
Number of subjects: 0
Study: 1925862

Group type: EXPERIMENTAL
Intervention: Surgical treatment followed by radiation therapy (102 patients), total dose of 45 to 55 Grays delivered to specific areas.
Number of subjects: 221

Group type: COMPARATOR
Intervention: Isolated surgical treatment (119 patients).
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Surgical treatment followed by radiation therapy (102 patients).
Number of subjects: 221
Study: 6958488

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms daily for 4 months
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Budesonide and Placebo
Number of subjects: 19
Study: 31262105

Group type: EXPERIMENTAL
Intervention: Children's Sleep Questionnaire (PSQ)
Number of subjects: 11420

Group type: EXPERIMENTAL
Intervention: Age groups comparison
Number of subjects: 11420

Group type: EXPERIMENTAL
Intervention: Gender comparison
Number of subjects: 11420

Group type: EXPERIMENTAL
Intervention: Various sleep-related factors
Number of subjects: 11420
Study: 29182350

Group type: EXPERIMENTAL
Intervention: 4 Pillars Practice Transformation Program
Number of subjects: 4737
Study: 25257982

Group type: EXPERIMENTAL
Intervention: Active waterpipe tobacco (preferred brand/flavor)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (flavor‐matched tobacco‐free waterpipe product)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both Active and Placebo
Number of subjects: 80
Study: 24401041

Group type: EXPERIMENTAL
Intervention: Intervention Group (Antenatal Asthma Management Service)
Number of subjects: 378

Group type: COMPARATOR
Intervention: Standard Care Group
Number of subjects: 378
Study: 22252927

Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) - 24 sessions over 12 weeks, twice weekly.
Number of subjects: 47
Study: 19463151

Group type: EXPERIMENTAL
Intervention: HX575 (100 IU/kg body weight, intravenous, three-times-weekly for four weeks)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Comparator epoetin alfa (100 IU/kg body weight, intravenous, three-times-weekly for four weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: HX575 and comparator epoetin alfa
Number of subjects: 80
Study: 17470000

Group type: EXPERIMENTAL
Intervention: Sellers (participants given a good to sell)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Choosers (participants given a choice between a good and cash)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Altering the order of queries posed
Number of subjects: 0
Study: 15023749

Group type: EXPERIMENTAL
Intervention: Lymphatic mapping and sentinel lymph node (SLN) biopsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very sensitive assays based on reverse transcriptase polymerase chain reaction technology
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ultrastaging by examining SLNs, peripheral blood, and bone marrow
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lymphatic mapping procedure
Number of subjects: 0
Study: 12145433

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 9795453

Group type: EXPERIMENTAL
Intervention: 90-ml oral sodium phosphate (NaP)
Number of subjects: 46

Group type: COMPARATOR
Intervention: X-Prep
Number of subjects: 46

Group type: COMPARATOR
Intervention: 45-ml oral sodium phosphate (NaP)
Number of subjects: 46
Study: 7709404

Group type: EXPERIMENTAL
Intervention: Picotamide (300 mg TID)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: Picotamide vs Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Picotamide
Number of subjects: 50
Study: 2796621

Group type: EXPERIMENTAL
Intervention: Aminophylline 2 mg/kg iv
Number of subjects: 80

Group type: COMPARATOR
Intervention: Physostigmine 1 mg iv and naloxone 0.4 mg im
Number of subjects: 80
Study: 66567

Group type: EXPERIMENTAL
Intervention: Metiamide (nocturnal administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metiamide (continued administration for 1 year)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metiamide (cessation of treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metiamide (repeated short courses for 1 month)
Number of subjects: 0
Study: 31475495

Group type: EXPERIMENTAL
Intervention: Medication (Climen, 1 tablet/d for 21 days)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acupuncture (manual stimulation of specific points from day 8 to 15 of menstruation, once daily for 3 cycles)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined treatment (acupuncture + medication)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined treatment vs Acupuncture
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined treatment vs Medication
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Acupuncture vs Medication
Number of subjects: 100
Study: 28922018

Group type: EXPERIMENTAL
Intervention: 0.03% tacrolimus ointment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 20
Study: 25914961

Group type: EXPERIMENTAL
Intervention: Individualized exercise program (90 minutes or more of low to moderate aerobic, resistance, core stability, and balance exercise per week for 12 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Individualized exercise program
Number of subjects: 30
Study: 23302981

Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of gastric volume using Right lat CSA measurement
Number of subjects: 108

Group type: COMPARATOR
Intervention: Previous models of ultrasound gastric volume assessment
Number of subjects: 108
Study: 21672493

Group type: EXPERIMENTAL
Intervention: ziprasidone, 20‐80 mg twice a day
Number of subjects: 298

Group type: COMPARATOR
Intervention: placebo twice a day
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: ziprasidone
Number of subjects: 298

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 298
Study: 18636953

Group type: EXPERIMENTAL
Intervention: Parenteral MenB outer membrane vesicle vaccine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (unvaccinated subjects)
Number of subjects: 21
Study: 16882446

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meningococcal vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae (Hib) vaccination
Number of subjects: 0
Study: 12971704

Group type: EXPERIMENTAL
Intervention: Perceptual learning exercises on hardness discrimination using three different levels of hardness of a rubber sponge for 10 days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 28
Study: 11078240

Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.2 to 3.6 microg/kg/min)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 8658295

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1419223

Group type: COMPARATOR
Intervention: Astemizole 5 mg daily for 2 weeks followed by increasing doses (5, 10, 20, 40 mg per day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Astemizole 10 mg daily for 12 weeks
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Astemizole plus DMA
Number of subjects: 69
Study: 3976329

Group type: EXPERIMENTAL
Intervention: Dorsal nerve block (DNB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Caudal analgesia
Number of subjects: 50
Study: 30643081

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitor (PPI) - esomeprazole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Histamine H2 receptor antagonist (H2 blocker) - famotidine
Number of subjects: 40
Study: 30157577

Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-pulsatile perfusion (NP)
Number of subjects: 60
Study: 27814722

Group type: EXPERIMENTAL
Intervention: Tobacco Tactics intervention
Number of subjects: 1370

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1370
Study: 24183511

Group type: EXPERIMENTAL
Intervention: BioOss® mixed with autogenous bone marrow concentrate
Number of subjects: 12

Group type: COMPARATOR
Intervention: BioOss® mixed with autogenous bone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 12
Study: 22249480

Group type: COMPARATOR
Intervention: Conventional laryngoscopy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional laryngoscopy and Intubating laryngeal mask airway
Number of subjects: 42
Study: 20077670

Group type: COMPARATOR
Intervention: Domestic split influenza virus vaccine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Imported split influenza virus vaccine
Number of subjects: 12
Study: 17341027

Group type: EXPERIMENTAL
Intervention: 250 mg flucloxacillin capsules
Number of subjects: 20
Study: 15468014

Group type: EXPERIMENTAL
Intervention: Simple walking task
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dual-motor task
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dual-cognitive task
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multiple task
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive function (Brixton test)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physical fatigue
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Balance (Berg Balance Scale)
Number of subjects: 30
Study: 11226790

Group type: EXPERIMENTAL
Intervention: Refractive multifocal intraocular lens (MIOL)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Monofocal intraocular lens (IOL)
Number of subjects: 231
Study: 9742717

Group type: EXPERIMENTAL
Intervention: Congruent priming trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incongruent priming trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subliminal priming effects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regression analysis of prime perceptibility
Number of subjects: 0
Study: 7761016

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anaesthesia (TIVA): propofol + fentanyl + pancuronio bromide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Balanced Narcosis: TPS + Isoflurane + Pancuronio bromide
Number of subjects: 40
Study: 3260794

Group type: EXPERIMENTAL
Intervention: Magnesium chloride 16 mmol in 10 ml of water
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10 ml of water alone (control group)
Number of subjects: 20
Study: 29878340

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg IV infusion
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 28157100

Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg for 6 weeks and 10 mg for 18 weeks)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 313
Study: 26212528

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 24147138

Group type: EXPERIMENTAL
Intervention: Inquiry-based learning pedagogy training
Number of subjects: 52

Group type: COMPARATOR
Intervention: General instructional 'best practices' training
Number of subjects: 52
Study: 21392951

Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy (using increased expiratory acceleration)
Number of subjects: 0
Study: 17571933

Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 34

Group type: COMPARATOR
Intervention: Er,Cr:YSGG laser‐assisted technique
Number of subjects: 34

Group type: COMPARATOR
Intervention: Erbium:YAG lasers laser‐assisted technique
Number of subjects: 34
Study: 15370722

Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Alprostadil
Number of subjects: 21
Study: 11210994

Group type: EXPERIMENTAL
Intervention: Doxorubicin with strontium-89 (Sr-89)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Doxorubicin alone
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Overall population (103 patients)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Patients with bone pain at registration
Number of subjects: 103
Study: 9434648

Group type: EXPERIMENTAL
Intervention: Reduced-fat diet (ad libitum) with dietary assessment and education followed by monthly meetings to reduce fat intake (months 1-6)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Reduced-fat diet (ad libitum)
Number of subjects: 39
Study: 8006643

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN) therapy
Number of subjects: 42
Study: 2574958

Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg/day) and distigmine (10 mg/day)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Distigmine alone
Number of subjects: 65

Group type: COMPARATOR
Intervention: Amitriptyline alone
Number of subjects: 65

Group type: COMPARATOR
Intervention: Addition of distigmine to preexisting amitriptyline treatment
Number of subjects: 65
Study: 1139387

Group type: COMPARATOR
Intervention: Atropine 0.4 mg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 0.2 mg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Atropine (intravenous)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate (intramuscular)
Number of subjects: 98
Study: 29803343

Group type: COMPARATOR
Intervention: Fio2 21%
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fio2 28%
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fio2 40%
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fio2 21% to 40%
Number of subjects: 46
Study: 28606061

Group type: EXPERIMENTAL
Intervention: Metacognitive-oriented social skills training (MOSST), 16 group sessions
Number of subjects: 12
Study: 26221786

Group type: EXPERIMENTAL
Intervention: Multimedia Presentation (MMP) for informed consent process
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard verbal consent
Number of subjects: 184
Study: 23992557

Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily for patients >70 kg or 0.5 mg once daily for patients ≤70 kg)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 240
Study: 20717856

Group type: EXPERIMENTAL
Intervention: Titanium, tapered, proximally coated stem
Number of subjects: 102

Group type: COMPARATOR
Intervention: Co‐Cr, cylindrical, extensively coated stem
Number of subjects: 102
Study: 18679038

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Responder group (depressive patients responding to treatment)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Unresponsive group (depressive patients not responding to treatment)
Number of subjects: 32
Study: 16544257

Group type: EXPERIMENTAL
Intervention: Combination therapies (specific types not detailed)
Number of subjects: 3072

Group type: EXPERIMENTAL
Intervention: Intermittent presumptive therapy, improved case management, and reduction in transmission intensity
Number of subjects: 3072
Study: 15230074

Group type: EXPERIMENTAL
Intervention: Opioid agonist treatment (n = 203)
Number of subjects: 358

Group type: COMPARATOR
Intervention: Medication-free treatment (n = 155)
Number of subjects: 358
Study: 11473971

Group type: EXPERIMENTAL
Intervention: Lofexidine hydrochloride (up to 600 mg twice daily over 8 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 9651412

Group type: EXPERIMENTAL
Intervention: IRT screening
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: IRT/DNA method
Number of subjects: 135

Group type: COMPARATOR
Intervention: Early treatment group
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study: 7737233

Group type: EXPERIMENTAL
Intervention: Tegretol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Temporol
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Karazepin
Number of subjects: 5
Study: 2600210

Group type: EXPERIMENTAL
Intervention: TRUE Test patch test system
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: TRUE Test screening allergens
Number of subjects: 128
Study: 1177471

Group type: EXPERIMENTAL
Intervention: Parietal-cell vagotomy alone (without drainage)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Selective vagotomy with antrectomy
Number of subjects: 23

Group type: COMPARATOR
Intervention: Truncal vagotomy with antrectomy
Number of subjects: 23
Study: 30372440

Group type: EXPERIMENTAL
Intervention: Cash-based intervention (CBI) - monthly unconditional cash transfer of US$84.00 for 5 months, non-food-items kit distribution, provision of piped water free of charge.
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Cash-based intervention (CBI)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 155
Study: 27560540

Group type: EXPERIMENTAL
Intervention: Guanidinoacetic acid (GAA) 3.0 g/day
Number of subjects: 5

Group type: COMPARATOR
Intervention: Creatine
Number of subjects: 5
Study: 24857002

Group type: EXPERIMENTAL
Intervention: OM-85 BV
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 21344468

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 2
Study: 20467188

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day for 16 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no pioglitazone)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Pioglitazone group (subgroup with higher baseline plasma AII)
Number of subjects: 50
Study: 18854110

Group type: EXPERIMENTAL
Intervention: Wallace catheter
Number of subjects: 308

Group type: COMPARATOR
Intervention: Rocket catheter
Number of subjects: 308
Study: 15796641

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CBT combined with hypnosis (CBT-hypnosis)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: CBT-hypnosis
Number of subjects: 87

Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 87
Study: 12423297

Group type: EXPERIMENTAL
Intervention: Powered toothbrush (Philips Jordan Sensiflex 2000) with electronic data logger
Number of subjects: 17
Study: 10426871

Group type: EXPERIMENTAL
Intervention: Coronary angioplasty
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stenting of the infarct artery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complete revascularization
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mechanical circulatory support with intra-aortic balloon pump
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart transplantation
Number of subjects: 0
Study: 7580386

Group type: EXPERIMENTAL
Intervention: Consent to observation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consent to observe only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Consent to observe and videotape
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Concerns expressed by patients who agreed to observation
Number of subjects: 0
Study: 1657527

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT) followed by medical treatment if needed to control intraocular pressure (IOP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 0
Study: 7204470

Group type: EXPERIMENTAL
Intervention: Knee-hinged cast-brace
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment on a Thomas' splint
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramedullary nailing
Number of subjects: 0
Study: 31088302

Group type: EXPERIMENTAL
Intervention: Extended thromboprophylaxis with oral anticoagulation
Number of subjects: 1849535
Study: 29083953

Group type: EXPERIMENTAL
Intervention: Culprit-lesion-only PCI
Number of subjects: 706

Group type: COMPARATOR
Intervention: Multivessel PCI
Number of subjects: 706